Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Overall survival
研究概览
简要总结
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.
Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.
详细描述
The study consists of a screening period, study drug period, end of study drug visit and follow-up period.
During the screening period, participants will be asked to have tests and procedures done to make sure that they are eligible to continue in the study. Screening may take several visits. Participants found to be eligible to continue in the study, will then enter the study drug period where they will take the study drug and have tests and procedures done about once a week for safety and for research purposes.
Participants who stop the study drug completely for any reason, will be asked to return to the clinic for an end of study drug visit about 28 days after their last dose of study drug to have tests and procedures done for safety and for research purposes. Participants that are experiencing any side effects during this time, will be closely followed by their study Doctor until the side effects have resolved or stabilized.
Participants who discontinue study drug for any reason other than disease progression, will be asked to have radiological imaging every 8 weeks to follow up on the status of their disease, until disease progression or the start a new treatment for their cancer.
After their final visit, the study nurse will call participants approximately every 3 months to check on the status of their health.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort 1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3) tested in either plasma or tissue, as applicable
- •18 years of age or older.
- •Measurable disease as per RECIST v1.
- •Adequate hematologic and organ function within 7 days of the proposed start date of treatment and adequate cardiac function within 28 days of the proposed start date of treatment
- •Life expectancy >12 weeks.
- •Have the ability to understand and the willingness to sign a written informed consent document
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- •No contraindication to Crizotinib therapy
- •Able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
- •No pregnant
- •Agree to use methods (as agreed upon by the study doctor and participant) before the study and for at least 120 days after the last dose of study drug to prevent pregnancy
排除标准
- •Symptomatic untreated brain metastases.
- •Had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. targeted therapy or antibodies) within 4 weeks or radiotherapy within 2 weeks prior to the proposed first dose of study treatment.
- •Adverse events attributed to prior anti-cancer therapy > Grade 1 if clinically relevant.
- •Receiving medications or substances known to be strong inhibitors or inducers of CYP3A
- •Any known intolerance to agents structurally similar to crizotinib.
- •Congenital long QT syndrome or persistent corrected QT interval by Fredericia formula (QTcF) ≥ 500 msec.
- •Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues
研究组 & 干预措施
ROS1 Rearrangement
Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
干预措施: Crizotinib (Drug)
MET-amplification
Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
干预措施: Crizotinib (Drug)
MET-activating Mutation (exon 14)
Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
干预措施: Crizotinib (Drug)
结局指标
主要结局
Overall survival
时间窗: 2 years
Number of days from the date of randomization to the date of death
Edmonton Symptom Assessment Scale (ESAS) Score
时间窗: 5 years
Patient related symptom improvement evaluated by ESAS
Response Rate
时间窗: 5 years
Via RECIST 1.1
Progression-free survival
时间窗: 5 years
Via RECIST 1.1
Average Time-to-treatment Failure
时间窗: 5 years
Time from randomization to treatment discontinuation for any reason
EQ5D-5L Questionnaire Score
时间窗: 5 years
Patient preference/health related utility evaluated by EQ5D-5L Questionnaire
次要结局
未报告次要终点